YARROW BIOSCIENCE INC
YARWNASDAQ🏆 #3647 by market capEarnings Nov 4US Equity
$19.07▼ $0.41 (−2.10%)
Latest quoteTrack YARW
Get earnings, price moves & breaking news on Telegram
24h▼ 2.1%
7d▼ 2.4%
14d▼ 3.6%
30d▼ 20.8%
ytd▼ 34.2%
1y▲ 11.4%
🏦Market Cap
$180M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
371.5x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $19.07 – $19.50
- 52-Week Range
- $18.05 – $44.28
- Volume (shares)
- 10,490
- Avg Volume (shares)
- —
- Shares Outstanding
- 9.4M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $570,000
- Last Q Revenue
- $97,000
- P/E Ratio
- —
- P/S Ratio
- 371.5x
- EPS (TTM)
- $-21.85
- Dividend Yield
- —
- Dilution (1yr)
- −21.8%
YARROW BIOSCIENCE INC
YARWFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$570K▲ +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%▼ −4.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$30M▼ −31.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −2.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
666K▼ −21.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$4M YoY
StockOtter · stockotter.spaceAbout YARROW BIOSCIENCE INC
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.